InteRNA Technologies BV is a company.
Key people at InteRNA Technologies BV.
InteRNA Technologies BV was founded by Karl Rothweiler (Founder, Founding Investor, Member of the Supervisory Board).
InteRNA Technologies BV was founded by Karl Rothweiler (Founder, Founding Investor, Member of the Supervisory Board).
InteRNA Technologies B.V. is a clinical-stage Dutch biotechnology company developing proprietary RNA therapeutics, primarily microRNA (miRNA)-based drugs targeting cancer initiation and progression.[1][2][3] It builds a pipeline of miRNA mimics enabled by a third-generation lipid nanoparticle (LNP) drug delivery formulation, serving cancer patients with advanced solid tumors by addressing drug resistance through simultaneous regulation of multiple signaling pathways.[1][2] The lead candidate, INT-1B3, induces apoptosis, enhances immune surveillance, and recruits effector T-cells, initially targeting hepatocellular carcinoma (HCC) with potential in melanoma, triple-negative breast cancer (TNBC), and non-small cell lung cancer (NSCLC).[1] The company has raised $32.9M in funding, including a recent €2.7M Dutch government Clinical Innovation Credit to support INT-1B3 clinical validation, signaling strong growth momentum in RNA therapeutics.[3]
InteRNA Technologies, based in the Netherlands (with mentions of Bilthoven, Nijmegen, and Utrecht), emerged as a biotech focused on miRNA platforms for cancer.[1][3] Specific founding year and founders are not detailed in available sources, but the company has evolved from preclinical miRNA discovery and validation to a clinical-stage pipeline, highlighted by government-backed funding for lead candidate advancement.[1][3] A pivotal moment came with the €2.7M Clinical Innovation Credit award from the Dutch government via Rijksdienst voor Ondernemend Nederland, enabling clinical trials for INT-1B3 in solid tumors and marking its transition to human testing.[3]
(Note: Recent site content shifts toward a "molecular nano motor" (MNM) for broad intracellular delivery of DNA/RNA/proteins, potentially indicating platform evolution.[4])
InteRNA rides the RNA therapeutics wave, leveraging miRNA's multi-target precision amid surging demand for immunotherapies and next-gen delivery post-mRNA vaccine successes.[1][2] Timing aligns with rising sorafenib resistance in HCC and need for combo therapies in immuno-oncology, where market forces favor platforms hitting immune-cold tumors and relapse prevention.[1][3] It influences the ecosystem by advancing Dutch biotech innovation, securing public-private funding, and contributing to global shifts toward coordinated, pathway-agnostic cancer attacks over single-target drugs.[3]
InteRNA is poised for INT-1B3 Phase 1/2 trials in HCC and beyond, fueled by government support and $32.9M funding, with MNM delivery potentially expanding to non-oncology cargoes.[3][4] Trends like AI-driven miRNA design, LNP improvements, and combo immuno-oncology will accelerate its path, evolving influence from niche miRNA pioneer to broader RNA delivery leader. As RNA platforms mature, InteRNA's multi-target efficacy could redefine cancer control, delivering the coordinated anti-tumor impact patients urgently need.[1]
Key people at InteRNA Technologies BV.
